Pomerantz Appointed Lead Counsel in BioLineRx Securities Litigation

On April 3, 2023, U.S. District Judge Brian R. Martinotti, of the District of New Jersey, appointed Pomerantz LLP as Lead Counsel on behalf of Peter Catanese – the Lead Plaintiff, and the class, in In re BioLineRx Sec. Litig, 23-cv-41 (D.N.J.). This securities class action alleges that BioLineRx Ltd. misled investors regarding its ability to finance the development and commercial launch of products in its pipeline. BioLineRx is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company’s lead product candidate is Motixafortide, a stem cell mobilization treatment for patients with multiple myeloma (plasma cell cancer). Allegations against BioLineRx include that: (i) the Company failed to…